Akston Biosciences
Akston Biosciences is dedicated to accelerating the next revolution in pet health by designing, developing, and manufacturing species-specific protein therapeutics. They leverage their proprietary Ambifect® Fc-fusion platform to create innovative biologics and vaccines for veterinary use, with a focus on cost-effective, stable, and targeted treatments. The company operates a vertically integrated, GMP-compliant manufacturing facility in Beverly, Massachusetts, and collaborates with strategic partners to bring advanced therapies to market. Their mission is to provide pets with biotech therapies that improve their health and strengthen bonds with their families.
Industries
Nr. of Employees
medium (51-250)
Akston Biosciences
Beverly, Massachusetts, United States, North America
Products
Ambient‑stable Fc-fusion subunit vaccine (clinical-stage candidate)
A subunit vaccine construct consisting of a target antigen fused to an Fc domain formulated for stability at elevated temperatures to enable low-cost, high-volume distribution without cold-chain dependence.
Antigen-specific immunotherapy (autoimmune indication candidate)
Fc-fusion biologic designed to present disease-specific epitopes to the immune system to induce selective deletion or tolerance of autoreactive B or T cells.
Ultra‑long‑acting insulin biologics for companion animals
Modified insulin therapeutics engineered for once‑weekly dosing in dogs and cats through sequence modifications and Fc domain selection to extend half-life and maintain glucose-lowering control.
Therapeutic vaccine candidates for animal indications (chronic pain, atopic dermatitis, cancer targets)
Platform-derived therapeutic vaccine constructs targeting proteins implicated in chronic pain and atopic dermatitis, and immunotherapies for oncology indications in companion animals.
Ambient‑stable Fc-fusion subunit vaccine (clinical-stage candidate)
A subunit vaccine construct consisting of a target antigen fused to an Fc domain formulated for stability at elevated temperatures to enable low-cost, high-volume distribution without cold-chain dependence.
Antigen-specific immunotherapy (autoimmune indication candidate)
Fc-fusion biologic designed to present disease-specific epitopes to the immune system to induce selective deletion or tolerance of autoreactive B or T cells.
Ultra‑long‑acting insulin biologics for companion animals
Modified insulin therapeutics engineered for once‑weekly dosing in dogs and cats through sequence modifications and Fc domain selection to extend half-life and maintain glucose-lowering control.
Therapeutic vaccine candidates for animal indications (chronic pain, atopic dermatitis, cancer targets)
Platform-derived therapeutic vaccine constructs targeting proteins implicated in chronic pain and atopic dermatitis, and immunotherapies for oncology indications in companion animals.
Services
cGMP biologics manufacturing (CDMO)
Manufacture of GMP drug substance at multi-kilogram scale with integrated process development and GMP quality control support for veterinary biologics.
Process development and scale-up
Product-scale process development services including optimization for single-use systems and scale-up planning to support clinical and commercial supply.
Quality control and analytical testing
GMP QC laboratory testing and release assays including immunogenicity, binding, and neutralization assays to support clinical development and product release.
Preclinical study support and IND‑enabling studies
Execution and coordination of toxicology, safety pharmacology, in vivo assay validation, and large-animal studies required for IND submissions.
Licensing and commercialization partnerships
Structuring and executing licensing, development, supply, and commercialization agreements for veterinary biologics with global partners.
cGMP biologics manufacturing (CDMO)
Manufacture of GMP drug substance at multi-kilogram scale with integrated process development and GMP quality control support for veterinary biologics.
Process development and scale-up
Product-scale process development services including optimization for single-use systems and scale-up planning to support clinical and commercial supply.
Quality control and analytical testing
GMP QC laboratory testing and release assays including immunogenicity, binding, and neutralization assays to support clinical development and product release.
Preclinical study support and IND‑enabling studies
Execution and coordination of toxicology, safety pharmacology, in vivo assay validation, and large-animal studies required for IND submissions.
Licensing and commercialization partnerships
Structuring and executing licensing, development, supply, and commercialization agreements for veterinary biologics with global partners.
Expertise Areas
- Protein therapeutics (Fc-fusion) development
- Companion animal biologics and veterinary therapeutics
- Vaccine design and development (subunit/Fc-fusion)
- Ultra‑long‑acting insulin and endocrine biologics
Key Technologies
- Fc-fusion protein therapeutics
- Subunit vaccine design (antigen-Fc constructs)
- Species-specific Fc engineering
- FcRn-mediated half-life extension